GPCR: financial statements from SEC — TradeAlmanac

GPCR

Structure Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Research and development	67m	59m	55m	43m	33m	22m
Selling, general and administrative	23m	15m	16m	13m	13m	11m
Operating expenses	89m	74m	70m	56m	46m	33m
Operating income	−89m	−74m	−70m	−56m	−46m	−33m
Pre-tax income	−76m	−66m	−62m	−47m	−34m	−26m
Income tax	190,000	108,000	139,000	98,000	92,000	53,000
Net income	−76m	−66m	−62m	−47m	−34m	−26m
Earnings per share	−0.35	−0.37	−0.36	−0.27	−0.20	−0.18
Earnings per share, diluted	−0.35	−0.37	—	−0.27	−0.20	−0.18
Weighted average shares	217m	175m	173m	172m	172m	148m
Weighted average shares, diluted	217m	175m	—	172m	172m	148m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	316m	800m	103m	147m	152m	170m	172m	382m
Short-term investments	1.14bn	647m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	15m	−52m
Depreciation and amortisation	576,000	274,000
Share-based compensation	12m	6m
Capital expenditure	1m	314,000
Investing cash flow	−497m	34m
Financing cash flow	−2m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)